At LifeFlight Medical Services, research is a core part of how we deliver high-quality aeromedical care. As a leader in prehospital and retrieval medicine, we are committed to advancing clinical practice, improving patient outcomes, and strengthening safety through rigorous, real-world research. Our work is shaped by frontline experience, collaborative inquiry, and a belief that evidence-based care drives better results.
Take a look at our latest findings, published articles and case reports that help shape the future of our care.
Objective: To define and compare the incidence, patient demographics, tasking characteristics, and clinical features associated with packed red blood cell (PRBC) administration within the LifeFlight Medical Services (LFM) retrieval network during the 2024 calendar year.
Methods: A retrospective cohort study examined all LFM missions in 2024 involving PRBC administration. Missions were included when PRBCs were administered by, or at the direction of, an LFM doctor. Primary missions and interfacility transfers (IFT) were analysed and compared with the overall mission cohort. Collected variables included transport platform, indication for transfusion, patient demographics, blood product utilisation, wastage, and compliance with adjunctive therapies.
Results: Among 7791 missions, PRBCs were administered on 226 missions (2.9% of all missions), including 100 primary missions (7.6% of all primary missions) and 126 IFT’s (1.9% of all IFT’s). A total of 492 units were transfused, with 3.0% wastage. Primary trauma accounted for 59% of transfusions and medical/surgical causes for 41%, most commonly upper gastrointestinal bleeding. Rotary- wing and road- based platforms demonstrated the highest transfusion incidence. No significant age differences were identified between transfused and non- transfused patients. Compliance with blood warming, tranexamic acid, and calcium administration was high at 81%, 83%, and 85%, respectively. Use of O- positive blood in females under 50 years was rare, occurring in 0.3% of primary missions.
Conclusions: PRBC transfusion within LFM is infrequent but essential across all missions. This analysis provides the first com prehensive Australian description of real- world PRBC utilisation across retrieval platforms, supporting transfusion governance, operational planning, and future outcome- focused research within Australia.
Introduction: Adrenaline and noradrenaline are cornerstones of critical care. Traditionally, delivery of these drugs has been through central venous access due to concerns over the safety of peripheral venous access. However, central venous access also may lead to delays and complications, so there is increasing use of peripheral vasoactive drugs. There is evidence for the safety of peripheral administration in controlled theatre and intensive care settings but limited evidence in Prehospital and Retrieval Medicine. Methods: We conducted a prospective, observational cohort study including patients transferred by LifeFlight Medicine from April 2022 to August 2023. The primary outcome was to establish the safety of peripheral adrenaline and noradrenaline. Patients receiving adrenaline or noradrenaline via peripheral intravenous cannula were included and data on venous access, drug delivery, and complications during transfer was collected. Patients were followed to 24 h post arrival to the receiving facility. Results: A total of 656 patients were screened, 468 met the inclusion criteria. Patients were predominantly men (60%), median age of 64, 74% of patients were transferred by rotary wing. Noradrenaline was the most common infusion (72%) with a median dose of 0.1 μg/kg/min, and 0.13 μg/kg/min for adrenaline. The anterior cubital fossa was the most common infusion site (78%). Septic shock was the most common indication (47%). The median duration of infusion was 85 min. 93.4% of patients experienced no events with the peripheral infusion; of the remaining 31 patients, 13 (2.8%) had minor technical issues with drug delivery, 14 (3%) had minor complications affecting patient care and 4 (0.8%) required conversion to central access in transit. There were no tissue complications at 24 h follow-up. Conclusion: Our data suggests that adrenaline and noradrenaline may be safely administered peripherally in Prehospital and Retrieval Medicine environments, with a low overall risk of complications.
Research at LifeFlight is made possible through the generous support of community donations and competitive research grant funding. We are especially grateful to partners like the Emergency Medicine Foundation (EMF), whose ongoing support enables us to drive innovation and improve outcomes in pre-hospital and retrieval medicine. Continued investment in research helps our teams investigate meaningful questions, explore new treatments, refine clinical practices, and ultimately save the lives of Queenslanders.
Have questions about our research or want to learn more about our latest projects?
We’d love to hear from you!
Email us at: research@lifeflight.org.au